Up to 20% of acute myeloid leukemia (AML) patients present initially with hyperleukocytosis, placing them at increased risk for early mortality during induction. Yet, it is unknown whether hyperleukocytosis still retains prognostic value for AML patients undergoing hematopoietic stem cell transplantation (HSCT). Furthermore, it is unknown whether hyperleukocytosis holds prognostic significance when modern molecular markers such as FLT3-ITD and NPM1 are accounted for.
to the pathogenesis of the increased mortality seen in hyperleukocytosis patients are the aggregate detrimental effects of leukostasis, tumor lysis syndrome, and disseminated intravascular coagulation. While hyperleukocytosis is frequently defined at the 100 000 WBC threshold, adverse hyperleukocytosis associated phenomenon are also seen at lower WBC counts. 13 Hyperleukocytosis was defined as a WBC count of over 50 000 WBC/mL. Cytogenetic risk was assessed according to the European LeukemiaNet criteria. 14 Intensity of conditioning was determined according to EBMT published criteria. 15 Stem cell grafts consisted of either bone marrow (BM) or G-CSF mobilized peripheral blood (PB). All donors were HLA-matched according to standard criteria (locus-A, -B, -C, DRB1, -DQB1). Patients who had undergone a previous stem cell transplantation were excluded from the analysis. Grading of acute and chronic graft-versus-host disease (GVHD) was performed using established criteria.
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| Statistical analysis
The clinical end points evaluated were leukemia-free survival (LFS), relapse incidence (RI), nonrelapse mortality (NRM), acute and chronic GVHD, GVHD-free/relapse-free survival, defined as events including grade 3-4 acute GVHD, systemic therapy-requiring chronic GVHD, relapse, or death in the first post-HCT year (GRFS), and overall survival (OS). LFS was defined as survival with no evidence of relapse or progression. Relapse was defined as the reappearance of 5% BM blasts and/or extramedullary lesion due to specific blast cell infiltration. NRM was defined as death without evidence of relapse or progression. OS was defined as the time from ASCT to death, regardless of the cause. were more common in non-HL patients, whereas patients with WBC 100 K more frequently harbored favorable risk cytogenetics.
| Overall survival and relapse incidence
The cumulative incidence of relapse at 3 years was 24% (95% CI: 22% to 27%). LFS and OS at 3 years were 61% (95% CI: 58%-64%) and 66% (95% CI: 63%-69%), respectively. A univariate cox regression model (Supporting Information Table S1 ) demonstrated that RI was significantly increased in HL patients [29% for WBC 50 K-100 K (95% CI:
22%-37%), and 30% for WBC > 100 K (95% CI: 23%-36%) vs. 22% for non-HL patients (95% CI: 19%-25%); P 5 .013]. The three year LFS rate tended to be lower among patients with hyperleukocytosis but this did not reach statistical significance [55% (95% CI: 48%-63%) vs.
63% (95% CI: 59%-66%); P 5 .066). A similar trend was also noted for OS ( Figure 1 ). We also note that when we analyzed patients with hyperleukocytosis (>50K WBC) with regard to their FLT3-ITD/NPM1 mutational status we found that the 52 patients with FLT3-ITD mut / NPM1 wt had a significantly increased risk of RI compared to the other subgroups (Supporting Information Table S2 ).
| NRM and GVHD
Overall, 57 (13%) patients died of nonrelapse etiologies after HSCT.
Leukemia and GHVD constituted the most common causes of patient death both in non-HL and HL patients (Supporting Information Table S3 ). Overall, grade II-IV acute GVHD was seen in 24% (95% CI: 22% to 27) of the patients analyzed in this cohort, whereas grade III-IV acute GVHD was experienced by 8% (95% CI: 6%-10%) of patients. The cumulative incidence of chronic GVHD at 3 years was 42% (95% CI:
39%-45%), and the rate of extensive chronic GVHD was 22% (95% CI:
19%-24%). As shown in Supporting Information Table S1 , a univariate cox regression model indicated that the cumulative incidence of grade II-IV acute GVHD, chronic GVHD, and extensive chronic GVHD were comparable in each of the three groups (<50 K vs. 50 K-100 K vs.
100 K). The 3 year incidence of GRFS was significantly increased in patients with a WBC count < 50 K compared to HL patients (45% vs.
39% vs. 36%, respectively; P 5 .022).
| Impact of hyperleukocytosis on outcome according to donor type
To determine whether donor type, namely matched sibling donors (MSD) versus matched unrelated donor (MUD), influenced the 
| Multivariate analysis of factors impacting on clinical outcome
To assess the effect of hyperleukocytosis on patient outcome following transplant, we performed a multivariate analysis using the following covariates in the regression modeling: WBC at diagnosis, ELN cytogenetic risk category, FLT3-ITD status, patient age, donor type, and number of induction cycles to reach CR1. As illustrated in Table 2 and Figure 1 the analysis confirmed that increasing WBC count had a significant effect on clinical outcome. A WBC count of over 100 K had an adverse effect on RI (HR, 1.55; 95% CI, 1.14-2.12; P 5 .004), LFS (HR, 1.38; 95% CI, 1.07-1.78; P 5 .01), and OS (HR, 1.4; 95% CI, 1.07-1.84; P 5 .013). Of note, the effect of hyperleukocytosis on OS was limited only to HL of over 100 K as a WBC count of 50 K-100 K was not found to significantly affect OS (HR, 1.25; 95% CI, 0.91-1.7; P 5 .15).
GRFS rates were inferior in HL patients both in patients with HL > 50K
(HR, 1.3; 95% CI, 1.02-1.65; P 5 .03), and those with HL of over 100K
(HR, 1.38; 95% CI, 1.11-1.71; P 5 .002).
As summarized in Table 3 , grade II-IV acute GVHD, chronic GVHD, and extensive chronic GVHD rates were not significantly influenced by hyperleukocytosis of any degree. A focused analysis comparing the clinical outcome of patients with hyperleukocytosis of over 
| DISCUSSION
In this report of a large cohort of transplanted AML patients with hyperleukocytosis, we show that patients with hyperleukocytosis have a distinct clinical course resulting in increased RI and inferior leukemia free survival, GFRS and OS, all of which were prognostically independent of other standard clinical, cytogenetic, and molecular risk factors for adverse outcome in AML.
It still remains to be determined whether hyperleukocytotic AML is a distinct clinical entity, nevertheless our data suggest that patients presenting with hyperleukocytosis are significantly more likely to harbor the double mutation phenotype of FLT3 mut /NPM1 mut compared to their non-HL counterparts (50% vs. 19%, P < .001). Notably, HL patients also had an increased frequency of favorable risk cytogenetics.
While decidedly these observations do not constitute formal proof, they do hint at the possible unique biology of HL AML. We note that the data presented is strongly supported by observations made by the Study Alliance Leukemia study group where HL patients were also found to be more likely to be FLT3-ITD (45% vs. 16%) and NPM1 (44% vs. 24%) mutated. 18 The Alliance investigators also note that their HL cohort had fewer patients displaying adverse risk cytogenetics which is also in line with our data. Previous research from other groups has also documented an association between hyperleukocytosis and FLT3-ITD.
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Additional salient findings from our study included the following. 
